Hubbry Logo
Tuberoinfundibular pathwayTuberoinfundibular pathwayMain
Open search
Tuberoinfundibular pathway
Community hub
Tuberoinfundibular pathway
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Tuberoinfundibular pathway
Tuberoinfundibular pathway
Tuberoinfundibular pathway
View on Wikipedia
from Wikipedia

Tuberoinfundibular pathway shown in opaque blue, connecting that hypothalamus with the pituitary gland.

The tuberoinfundibular pathway refers to a population of dopamine neurons that project from the arcuate nucleus (a.k.a. the "infundibular nucleus") in the tuberal region of the hypothalamus to the median eminence.[1] It is one of the four major dopamine pathways in the brain. Dopamine released at this site inhibits the secretion of prolactin from anterior pituitary gland lactotrophs by binding to dopamine receptor D2.

Some antipsychotic drugs block dopamine in the tuberoinfundibular pathway, which can cause an increase in the amount of prolactin in the blood (hyperprolactinemia).

Other dopamine pathways

[edit]

Other major dopamine pathways include:

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Tuberoinfundibular pathway

View on Grokipedia
from Grokipedia
The tuberoinfundibular pathway, also known as the tuberoinfundibular dopaminergic (TIDA) pathway, is a neuronal circuit originating from dopamine-producing neurons in the arcuate nucleus (A12 group) and (A14 group) of the mediobasal , with axons projecting to the external zone of the , a circumventricular organ at the base of the brain. The role of in this pathway was established in the early 1970s, when it was identified as the primary prolactin-inhibiting factor (PIF) from the . There, is released into the hypophyseal portal blood system, serving as the primary prolactin-inhibiting factor (PIF) by tonically suppressing secretion from lactotroph cells in the gland via activation of D2 , which inhibit adenylate cyclase and reduce gene . This pathway plays a crucial role in maintaining hormonal balance, particularly in reproductive physiology, , and , as disruptions can lead to hyperprolactinemia, , , and metabolic dysregulation. The pathway's activity is regulated through a short-loop mechanism, where elevated levels stimulate release from TIDA neurons to restore balance, while gonadal steroids such as enhance and testosterone suppresses this tone. Additional modulation occurs via inputs from other neurotransmitters and neuropeptides, including serotonin, GABA, , oxytocin, and , which can excite or inhibit TIDA firing; for instance, oxytocin facilitates release during to fine-tune dynamics. Research as of 2023 has highlighted unique autoregulatory features, such as somatodendritic D2 receptors that control oscillatory firing patterns and synthesis through , contributing to the pathway's plasticity in response to physiological demands like and stress. Clinically, the tuberoinfundibular pathway is implicated in conditions involving antipsychotic-induced hyperprolactinemia, where D2 receptor blockade disrupts inhibition, and it remains relatively spared in compared to other systems.

Introduction

Definition and Overview

The tuberoinfundibular pathway, also known as the tuberoinfundibular (TIDA) pathway, is a neuronal circuit originating from dopamine-producing neurons in the arcuate nucleus (A12 cell group) and (A14 cell group) of the mediobasal . These neurons project short axons inferiorly from the through the infundibulum to the , where is released into the for transport to the gland. This pathway serves as a critical link in the hypothalamic-pituitary axis, integrating neural signals with endocrine regulation. The primary function of the tuberoinfundibular pathway is to deliver , its main , as the prolactin-inhibiting factor (PIF) to suppress the secretion of from lactotroph cells in the . binds to D2 receptors on these cells, providing tonic inhibition that maintains basal levels and prevents excessive hormone release under normal conditions. This regulatory mechanism ensures balanced hormone secretion, influencing broader neuroendocrine . The tuberoinfundibular pathway exhibits evolutionary conservation across mammals, reflecting its essential role in neuroendocrine integration for reproductive and metabolic functions. Dopaminergic inhibition of secretion traces back to early vertebrates, with adaptations in mammals enhancing its specificity for and maternal .

Historical Background

The discovery of the tuberoinfundibular pathway emerged from mid-20th-century studies on hypothalamic of pituitary function. In and 1940s, Geoffrey Harris conducted pioneering experiments demonstrating neural control of the through neurohumoral mechanisms, including electrical stimulation of the to induce in rabbits and pseudopregnancy in rats, as well as observations of hypophysial portal vessel blood flow directing hypothalamic factors to the pituitary. Harris's work in the 1950s further established that revascularization of the portal vessels restored pituitary function after stalk sectioning, laying the groundwork for understanding hypothalamic pathways influencing endocrine secretion. Concurrently, Arvid Carlsson's 1957 identification of as an independent in the , rather than merely a norepinephrine precursor, shifted focus toward its potential neuroendocrine roles. The pathway's anatomical and neurochemical features were elucidated in the 1960s using the Falck-Hillarp histofluorescence technique, developed in 1962 to visualize catecholamines via formaldehyde-induced fluorescence, distinguishing dopamine's green emission from noradrenaline's yellow. This method enabled Annica Dahlström and Kjell Fuxe in 1964 to map monoamine-containing neurons, identifying the A12 cell group in the arcuate nucleus of the as projecting axons to the infundibulum and . The name "tuberoinfundibular pathway" reflects this trajectory: "tubero" from the (a hypothalamic swelling) and "infundibular" from the infundibulum (the ), formalizing its description as a discrete neural route. By the early 1970s, biochemical assays confirmed these A12 neurons as , with measured in hypophysial portal blood. Key experiments in the 1970s solidified dopamine's identity as the prolactin-inhibiting factor (PIF). In 1970, Kamberi, Mical, and Porter demonstrated that intraventricular administration elevated PIF activity in rat hypophysial stalk blood, directly inhibiting release. Subsequent rat studies showed that pharmacological depletion of hypothalamic —via , which disrupts vesicular storage, or 6-hydroxydopamine (6-OHDA), a selective —led to marked elevations in serum levels, confirming tonic inhibition by this pathway. These findings, building on earlier observations that induced hyperprolactinemia and pseudopregnancy in rats, established the tuberoinfundibular system's primary role in regulation. By the 1980s, the pathway was integrated into the of four major systems—alongside nigrostriatal, mesolimbic, and mesocortical pathways—in comprehensive reviews synthesizing histochemical, biochemical, and data. The A12 group's classification as the core of the tuberoinfundibular pathway underscored its unique neuroendocrine function, distinct from other circuits involved in motor and reward processing.

Anatomy

Origin in the Hypothalamus

The tuberoinfundibular pathway originates from populations of neurons whose cell bodies are located in the arcuate nucleus (A12 group) and (A14 group) at the base of the . In humans, the arcuate nucleus is termed the infundibular nucleus. These neurons are positioned in the tuberal region, immediately adjacent to the floor of the third ventricle, integrating them into the mediobasal for precise neuroendocrine control. The A12 and A14 neurons exhibit small, morphology and form a relatively modest population. Many of these neurons co-express neuropeptides such as , enhancing their role in modulating hormonal signals beyond alone. This co-localization has been demonstrated through combined immunocytochemical techniques in models. Positioned in close proximity to the —a specialized neurohemal deficient in a traditional blood-brain barrier—the A12 and A14 neurons enable direct release of into the hypophyseal portal system. This anatomical arrangement supports the pathway's primary function in endocrine regulation without requiring synaptic transmission across vascular barriers. Developmentally, the A12 and A14 dopaminergic neurons arise from progenitor cells in the embryonic , part of the ventral . In , for these cells peaks during late , with hydroxylase-expressing neurons emerging around embryonic day 14.5 in the ventrolateral arcuate nucleus and day 15.5 in the dorsomedial region. This developmental pattern is conserved in humans, though specific timing differs due to extended .

Projection and Termination

The tuberoinfundibular pathway consists of short axonal projections originating from neurons in the arcuate nucleus of the mediobasal and extending through the toward the infundibulum. These axons traverse the tuberoinfundibular tract, a bundle of nerve fibers that avoids forming traditional synaptic connections along its course, instead maintaining a direct trajectory to the base of the . In , the pathway's neurons are primarily located in the dorsomedial arcuate nucleus, with projections terminating in the external zone of the , where they integrate closely with the hypophyseal portal system's capillary plexus. At their termination points, the axons of the tuberoinfundibular pathway end in close proximity to the fenestrated capillaries of the primary portal plexus in the , formed by branches of the superior hypophyseal artery. is released from these terminals into the perivascular spaces, entering the bloodstream of the hypophyseal portal veins that descend along the infundibular stalk to the . This vascular integration allows for the efficient transport of via the portal circulation, bypassing direct neural links and enabling its role as a circulating neurohormone. The portal system's unique structure, with its low-flow, high-permeability capillaries, facilitates rapid delivery without dilution into the systemic circulation. The pathway provides no direct innervation to the ; instead, its dopaminergic terminals release transmitters solely into the portal vasculature, influencing pituitary function indirectly through humoral mechanisms. diffuses from the into the portal blood, reaching lactotroph cells in the to exert inhibitory effects. This neurohemal organization distinguishes the tuberoinfundibular pathway from other systems that rely on synaptic transmission. Structural variations in the tuberoinfundibular pathway are evident across and physiological states, with the core conserved between humans and but showing differences in density and plasticity. In , projections are denser and exhibit morphological adaptations during , including significantly higher somatic spine density on tuberoinfundibular neurons compared to non-lactating states, which may enhance excitatory inputs and modulate axonal output. Human studies, limited by ethical constraints, indicate similar hypothalamic origins and portal system integration. These variations highlight the pathway's adaptability to hormonal demands, such as increased needs during .

Neurochemistry

Dopamine Biosynthesis

Dopamine biosynthesis in tuberoinfundibular (TIDA) neurons begins with the conversion of the L-tyrosine to L-3,4-dihydroxyphenylalanine () by the enzyme (TH), which serves as the rate-limiting step in the pathway. This reaction requires as a cofactor and molecular oxygen, occurring in the neuronal . L-DOPA is then rapidly decarboxylated to form by (AADC), also known as DOPA decarboxylase. Unlike noradrenergic or adrenergic neurons, TIDA neurons do not express β-hydroxylase, ensuring that dopamine remains the primary catecholamine product without conversion to norepinephrine. The synthesis of in TIDA neurons is dynamically regulated by through a short-loop mechanism. binds to its receptors on these neurons, activating the (JAK2)-signal transducer and activator of transcription 5 (STAT5) signaling pathway, which enhances TH at serine 40 and increases its enzymatic activity. This activation occurs rapidly, with JAK2 peaking within 15 minutes and STAT5 within 30-60 minutes, leading to elevated production that in turn suppresses secretion. Over longer periods, such as days, also upregulates TH via STAT5-mediated transcription. Once synthesized, dopamine is sequestered into synaptic vesicles by the vesicular monoamine transporter 2 (VMAT2) for storage and subsequent release. TIDA neurons also express the (DAT) on their axon terminals, which can mediate of extracellular into the . However, plays a minimal role in clearance compared to other dopaminergic systems, as is primarily released into the fenestrated capillaries of the for diffusion into the .

Release and Receptor Interactions

Dopamine release from tuberoinfundibular (TIDA) neurons occurs primarily through calcium-dependent at terminals in the , where the is secreted into the hypophysial portal vessels for transport to the . This process is triggered by action potentials propagating along the neuronal , leading to voltage-gated calcium influx that facilitates vesicle fusion and efflux. Unlike phasic release patterns in other systems, TIDA neurons maintain a tonic release profile characterized by low basal levels, ensuring continuous inhibition of secretion under normal conditions. The primary receptors mediating these effects are dopamine D2 receptors (D2R), expressed on the surface of pituitary lactotroph cells. These G_i/o-coupled receptors, upon binding , inhibit adenylate cyclase activity, thereby reducing intracellular cyclic AMP (cAMP) levels and suppressing synthesis and release. Additionally, D2 autoreceptors located on TIDA terminals and somata provide inhibition, modulating release by hyperpolarizing the neurons and dampening further in response to elevated extracellular concentrations. There is no significant involvement of D1 receptors in this pathway, as the inhibitory tone is predominantly D2-mediated. Activation of D2R on lactotrophs initiates a signaling cascade that includes G_i/o βγ subunit-mediated opening of G protein-coupled inward-rectifying potassium (GIRK) channels, leading to membrane hyperpolarization and reduced excitability. This hyperpolarization decreases opening, limiting calcium entry necessary for . Furthermore, the pathway inhibits transcription by repressing the PRL promoter through decreased cAMP-dependent signaling and direct interference with transcription factors. Estrogen modulates this system by suppressing TIDA release, primarily through downregulation of expression in TIDA neurons, which reduces synthesis and availability for release. This estrogen-induced inhibition facilitates surges in secretion during reproductive cycles.

Physiological Functions

Prolactin Regulation

The tuberoinfundibular pathway exerts tonic inhibition on secretion from lactotrophs via continuous low-level release from tuberoinfundibular (TIDA) neurons in the hypothalamic arcuate nucleus. This acts on D2 receptors to suppress synthesis and release, maintaining basal levels below 20 ng/mL in non-pregnant, non-lactating adults. Disruption of the pathway, such as through section, interrupts delivery to the pituitary, leading to hyperprolactinemia with levels typically ranging from 25 to 200 ng/mL. A short-loop negative feedback mechanism regulates this interaction, where elevated stimulates TIDA neurons via prolactin receptors, activating signal transducer and activator of transcription 5 (STAT5) signaling in the arcuate nucleus to enhance biosynthesis and release, thereby inhibiting further . This feedback ensures under varying physiological demands. follows circadian and pulsatile patterns, with nocturnal surges peaking between 2:00 and 4:00 a.m., modulated by corresponding inhibitory pulses of from TIDA neurons along the tuberoinfundibular pathway. During suckling, neural reflexes suppress TIDA neuron activity, transiently reducing release to permit surges essential for while overriding tonic inhibition. Species differences influence the strength of this dopaminergic control: in primates, including humans, dopamine provides robust tonic inhibition with minimal contributions from other factors, whereas in rodents, additional regulators like vasoactive intestinal peptide (VIP) play a more prominent role in prolactin stimulation, particularly during lactation.

Involvement in Reproduction and Stress

The tuberoinfundibular pathway plays a critical role in reproduction by regulating prolactin levels, which indirectly influence gonadotropin-releasing hormone (GnRH) secretion. Elevated prolactin, arising from diminished dopaminergic inhibition, suppresses GnRH release from hypothalamic neurons, thereby reducing luteinizing hormone and follicle-stimulating hormone secretion from the pituitary and impairing ovulation and fertility. Consequently, the tonic dopamine release from tuberoinfundibular neurons maintains basal prolactin at low levels to facilitate normal GnRH pulsatility and reproductive competence. Steroid hormones further integrate the pathway into reproductive cycles. enhances prolactin synthesis and release during the and , while progesterone dominates in the to fine-tune tone, supporting development and preparing for without disrupting timing. These cyclic modulations ensure prolactin surges align with physiological demands, such as maintenance and postpartum milk ejection. In stress responses, the pathway adapts prolactin output to balance reproductive priorities. Acute stressors, such as restraint or immobilization, typically suppress tuberoinfundibular activity, elevating to promote adaptive mechanisms like analgesia and immune modulation while temporarily prioritizing over . Chronic stress dysregulates this system through corticotropin-releasing factor (CRF) interactions, where CRF neurons in the paraventricular nucleus inhibit dopaminergic tone, leading to sustained hyperprolactinemia and potential reproductive suppression. The exemplifies pathway inhibition during reproduction. Suckling activates sensory afferents that suppress tuberoinfundibular neurons via and oxytocin release from paraventricular neurons, rapidly decreasing delivery to the and enabling surges essential for synthesis and ejection. This overrides basal inhibition, sustaining hyperprolactinemia throughout without affecting other hypothalamic functions. Aging impacts pathway efficiency, particularly post-menopause. Post-menopause, declining reduces its direct stimulation of prolactin synthesis and antagonism of inhibition, enhancing overall dopaminergic tone and lowering prolactin levels, which contributes to imbalances in gonadotropins and other hormones, exacerbating menopausal symptoms like irregular cycles and metabolic shifts. This age-related attenuation underscores the pathway's sensitivity to gonadal steroids in maintaining endocrine .

Clinical Significance

Associated Pathological Conditions

Dysfunction of the tuberoinfundibular pathway, which delivers inhibitory to the pituitary lactotrophs, can lead to hyperprolactinemia through impaired signaling. This disruption commonly occurs due to mechanical interference, such as pituitary stalk compression by suprasellar tumors or other lesions, which interrupts the delivery of from hypothalamic neurons to the . Resulting hyperprolactinemia manifests clinically with symptoms including (inappropriate milk production), amenorrhea (absence of menstrual cycles), and , particularly in women of reproductive age. The condition affects less than 1% of the general , with estimates around 0.4% in unselected adults and up to 5% among women seeking care for reproductive issues. Hypoprolactinemia, in contrast, arises from excessive tone along the tuberoinfundibular pathway, which overly suppresses secretion and is relatively rare. Common causes include treatment with dopamine agonists, which mimic or enhance 's inhibitory effects on lactotrophs; in cases of levodopa overdose, the precursor's conversion to excess can similarly suppress release. This leads to impaired and potential failure of initiation postpartum, though isolated hypoprolactinemia often presents asymptomatically unless associated with broader pituitary dysfunction. Prolactinomas, benign pituitary adenomas composed of lactotroph cells, represent a key linked to tuberoinfundibular dysfunction, as tumor growth can reduce access of to pituitary receptors, thereby diminishing tonic inhibition and promoting autonomous secretion. Genetic or experimental disruptions in tuberoinfundibular production further underscore this mechanism, resulting in markedly elevated levels and adenoma-like proliferation. Additionally, in , while the primary pathology involves nigrostriatal degeneration, the tuberoinfundibular pathway remains relatively unaffected compared to other dopaminergic systems. Diagnosis of pathological conditions involving the tuberoinfundibular pathway relies on serum prolactin measurement, where levels exceeding 100 ng/mL strongly indicate organic etiologies such as stalk disruption or prolactinomas, distinguishing them from physiological or mild pharmacologic elevations. Levels above 500 ng/mL are particularly suggestive of macroprolactinomas, prompting to assess pathway integrity. Confirmation typically involves repeat testing to rule out transient factors, ensuring accurate attribution to underlying tuberoinfundibular impairment.

Therapeutic Targeting

The tuberoinfundibular pathway is a primary target for pharmacological interventions aimed at modulating secretion in endocrine disorders, particularly hyperprolactinemia. agonists, which mimic the inhibitory effects of endogenous released from arcuate nucleus A12 neurons onto pituitary lactotrophs via D2 receptors, represent the cornerstone of treatment for conditions such as prolactinomas and idiopathic hyperprolactinemia. , an ergot-derived D2 receptor agonist, effectively normalizes levels and reduces tumor size in prolactin-secreting pituitary adenomas by enhancing tone in the pathway. , another ergot-derived D2 agonist, similarly treats hyperprolactinemia by activating D2 receptors in the pituitary, leading to suppression, and is often preferred over due to its longer elimination half-life of approximately 65 hours, allowing for less frequent dosing (typically twice weekly). Antipsychotic medications frequently impact the tuberoinfundibular pathway through D2 receptor blockade, resulting in iatrogenic hyperprolactinemia as a common adverse effect. Typical antipsychotics like , which potently antagonize D2 receptors, disrupt the pathway's inhibitory control on release, elevating serum levels in 30-50% of chronic users and contributing to symptoms such as and . In contrast, atypical antipsychotics such as aripiprazole act as partial D2 agonists, preserving pathway function and often lowering levels without causing significant elevation, making them suitable for patients at risk of endocrine disruption. Other modulators of the pathway include antiemetics like metoclopramide, a peripheral primarily used for gastrointestinal disorders such as . While effective for its intended indications, metoclopramide inhibits signaling in the tuberoinfundibular pathway, leading to elevation in more than 50% of patients and necessitating monitoring for hyperprolactinemia-related complications. Emerging therapeutic strategies focus on restoring tuberoinfundibular pathway function in refractory hyperprolactinemia cases. Preclinical studies have explored approaches, such as delivery of glial cell line-derived neurotrophic factor (GDNF) or insulin-like growth factor-I (IGF-I) to the arcuate nucleus, to rejuvenate A12 neurons and ameliorate chronic hyperprolactinemia in animal models of aging or pituitary adenomas. These interventions aim to enhance neuronal survival and synthesis, offering potential for cases unresponsive to conventional agonists, though clinical translation remains in early stages.

Relation to Other Dopaminergic Pathways

Structural and Functional Comparisons

The (TIP), originating from neurons in the arcuate nucleus (A12 cell group) of the , features short axonal projections that terminate in the , where is released into the hypophyseal portal vasculature for direct delivery to the gland. In contrast, the arises from the pars compacta (A9 cell group) and extends long, synaptic projections to the dorsal striatum, facilitating precise neural communication within the . Functionally, the TIP primarily exerts tonic inhibitory control over secretion in the pituitary, serving a neuroendocrine role, whereas the modulates and voluntary movement, with disruptions linked to conditions like . Compared to the , which originates in the (VTA; A10 cell group) and projects to limbic structures such as the , the TIP employs predominantly tonic release to sustain inhibition of hormone release, rather than the phasic bursts characteristic of mesolimbic signaling that drive reward anticipation and . The TIP's vascular, non-synaptic delivery mechanism bypasses traditional synaptic clefts, differing from the mesolimbic pathway's reliance on synaptic transmission in extrahypothalamic regions for emotional and motivational processing. The , also stemming from the VTA, sends projections to the to influence cognitive functions like executive control and , in opposition to the TIP's targeted endocrine modulation of pituitary hormones without extensive cortical involvement or axonal collaterals. Unlike the mesocortical pathway's role in higher-order cognition, the TIP lacks broad collateralization and focuses on localized hypophyseal regulation, highlighting its specialized neuroendocrine architecture. All four major utilize as the primary neurotransmitter and predominantly act through D2 receptors to mediate their effects, yet the TIP is distinguished by its unique circumvention of the blood-brain barrier via the portal system, enabling direct hormonal influence on peripheral endocrine targets.

Interactions and Overlaps

Pharmacological agents like antipsychotics exert effects across multiple , including the TIP, nigrostriatal, and mesolimbic systems, leading to shared disruptions in signaling. However, the TIP-specific blockade of D2 receptors distinctly elevates levels, differentiating it from motor side effects like that arise primarily from nigrostriatal antagonism. Inputs from raphe serotonin neurons integrate with the TIP, enhancing dopaminergic tone in arcuate neurons during reproductive contexts to fine-tune hormone release. This serotonergic modulation supports network-level coordination, influencing inhibition amid reproductive demands.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC10778701/
  2. https://academic.oup.com/edrv/article/22/6/724/2424026
  3. https://www.sciencedirect.com/topics/neuroscience/tuberoinfundibular-pathway
  4. https://www.e-enm.org/journal/view.php?doi=10.3803/EnM.2021.979
  5. https://www.ncbi.nlm.nih.gov/books/NBK507829/
  6. https://www.mdpi.com/1422-0067/25/1/110
  7. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00621/full
  8. https://joe.bioscientifica.com/view/journals/joe/226/2/T13.xml
  9. https://pubmed.ncbi.nlm.nih.gov/9056724/
  10. https://www.nobelprize.org/prizes/medicine/2000/press-release/
  11. https://www.sciencedirect.com/science/article/abs/pii/S0301008209001634
  12. https://pubmed.ncbi.nlm.nih.gov/14229500/
  13. https://pubmed.ncbi.nlm.nih.gov/5483776/
  14. https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2826.2008.01736.x
  15. https://joe.bioscientifica.com/view/journals/joe/226/2/T101.xml
  16. https://pubmed.ncbi.nlm.nih.gov/17408759/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC11837187/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC10789173/
  19. https://www.researchgate.net/publication/376736561_Current_Review_of_the_Function_and_Regulation_of_Tuberoinfundibular_Dopamine_Neurons
  20. https://academic.oup.com/endo/article/166/3/bqaf025/8005248
  21. https://www.sciencedirect.com/science/article/abs/pii/0006899383909782
  22. https://doi.org/10.3390/ijms25010110
  23. https://nba.uth.tmc.edu/neuroscience/m/s4/chapter02.html
  24. https://www.ncbi.nlm.nih.gov/books/NBK279126/
  25. https://doi.org/10.1111/jne.12884
  26. https://www.ncbi.nlm.nih.gov/books/NBK535451/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC3065393/
  28. https://www.mdpi.com/2073-4409/14/9/642
  29. https://academic.oup.com/endo/article/146/12/5112/2500008
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC6704969/
  31. https://academic.oup.com/endo/article/141/1/366/2988509
  32. https://pubmed.ncbi.nlm.nih.gov/3736788/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC6529860/
  34. https://pubmed.ncbi.nlm.nih.gov/18096663/
  35. https://pubmed.ncbi.nlm.nih.gov/27149844/
  36. https://pubmed.ncbi.nlm.nih.gov/8163504/
  37. https://pubmed.ncbi.nlm.nih.gov/1835974/
  38. https://pubmed.ncbi.nlm.nih.gov/19744546/
  39. https://pubmed.ncbi.nlm.nih.gov/8722750/
  40. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2018.00768/full
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC6620951/
  42. https://www.ncbi.nlm.nih.gov/books/NBK537331/
  43. https://onlinelibrary.wiley.com/doi/10.1111/jne.70098
  44. https://pubmed.ncbi.nlm.nih.gov/3109881/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC2244934/
  46. https://karger.com/hrp/article/65/1/31/372789/Prolactin-Suppresses-GnRH-but-Not-TSH-Secretion
  47. https://journals.physiology.org/doi/full/10.1152/physrev.2000.80.4.1523
  48. https://pubmed.ncbi.nlm.nih.gov/1728724/
  49. https://pubmed.ncbi.nlm.nih.gov/4058676/
  50. https://onlinelibrary.wiley.com/doi/10.1155/2018/9253083
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC3288386/
  52. https://www.sciencedirect.com/science/article/abs/pii/S0278584620302578
  53. https://pubmed.ncbi.nlm.nih.gov/9272425/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC2668659/
  55. https://www.mdpi.com/2077-0383/8/12/2203
  56. https://emedicine.medscape.com/article/121784-overview
  57. https://bestpractice.bmj.com/topics/en-us/538
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC11624249/
  59. https://www.nejm.org/doi/abs/10.1056/NEJM197111182852102
  60. https://www.mdpi.com/1422-0067/22/20/11247
  61. https://karger.com/nen/article-abstract/86/1/48/225920
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC3363356/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC6502148/
  64. https://emedicine.medscape.com/article/121784-clinical
  65. https://www.ncbi.nlm.nih.gov/books/NBK555948/
  66. https://www.sciencedirect.com/topics/medicine-and-dentistry/cabergoline
  67. https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2961587-5/fulltext
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC4022988/
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC2854198/
  70. https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-7-13
  71. https://doi.org/10.1007/s10571-018-0632-3
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC5624946/
  73. https://psychopharmacologyinstitute.com/publication/the-four-dopamine-pathways-relevant-to-antipsychotics-pharmacology-2096/
  74. https://www.frontiersin.org/journals/integrative-neuroscience/articles/10.3389/fnint.2013.00060/full
Add your contribution
Related Hubs
User Avatar
No comments yet.